Johnson & Johnson-JNJ-Q1 FY-26 Earnings Call Note-pushing worldwide revenue to $24.1 billion
Johnson & Johnson reported Q1 FY2026 earnings with a significant operational sales growth of 6.4%, reaching $24.1 billion, despite challenges from STELARA patent losses. The Innovative Medicine segment thrived, converting potential losses into gains through new drugs. Management remains optimistic about achieving $100 billion in revenue, boosting full-year guidance.
You must be logged in to post a comment.